A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Inclusion Criteria:

• Histological confirmation of NASH, defined as NAFLD Activity Score (NAS) ≥4 with ascore ≥1 point in each component (steatosis, ballooning, and lobular inflammation)AND NASH clinical research network (CRN) fibrosis score of Stage 2 or 3

• No history of Type 2 diabetes mellitus (T2DM) OR a history of T2DM with an A1C ≤9%that is controlled by diet or stable doses of antihyperglycemic agents (AHAs)

• Participants in South Korea are eligible between the ages of 19 to 80 years of age (inclusive)

Exclusion Criteria:

• History of liver disease other than NASH

• History or evidence of cirrhosis

• History of pancreatitis

• History of Type 1 diabetes mellitus (T1DM), diabetic ketoacidosis, or diabetessecondary to pancreatectomy

• History of a bariatric surgical procedure ≤5 years before study entry, or a knownclinically significant gastric emptying abnormality

• Has significant systemic or major illnesses, including recent events (≤6 monthsbefore study entry) of congestive heart failure, unstable angina, myocardialinfarction, arterial revascularization, stroke, or transient ischemic attack